BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dannenfelser R, Allen GM, VanderSluis B, Koegel AK, Levinson S, Stark SR, Yao V, Tadych A, Troyanskaya OG, Lim WA. Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies. Cell Syst 2020;11:215-228.e5. [PMID: 32916097 DOI: 10.1016/j.cels.2020.08.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Bechtel TJ, Bertoch JM, Olow AK, Duich M, White CH, Reyes-Robles T, Fadeyi OO, Oslund RC. Proteomic mapping of intercellular synaptic environments via flavin-dependent photoredox catalysis. Org Biomol Chem 2022;21:98-106. [PMID: 36477737 DOI: 10.1039/d2ob02103j] [Reference Citation Analysis]
2 Allen GM, Lim WA. Rethinking cancer targeting strategies in the era of smart cell therapeutics. Nat Rev Cancer 2022;22:693-702. [PMID: 36175644 DOI: 10.1038/s41568-022-00505-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wang L, Chen X, Zhang L, Niu B, Li L, Sun Y, Yuan X. CAR cell design strategies in solid tumors. International Immunopharmacology 2022;113:109345. [DOI: 10.1016/j.intimp.2022.109345] [Reference Citation Analysis]
4 Irvine DJ, Maus MV, Mooney DJ, Wong WW. The future of engineered immune cell therapies. Science 2022;378:853-858. [DOI: 10.1126/science.abq6990] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Corridon PR, Wang X, Shakeel A, Chan V. Digital Technologies: Advancing Individualized Treatments through Gene and Cell Therapies, Pharmacogenetics, and Disease Detection and Diagnostics. Biomedicines 2022;10:2445. [PMID: 36289707 DOI: 10.3390/biomedicines10102445] [Reference Citation Analysis]
6 Tang R, Fu Y, Gong B, Fan Y, Wang H, Huang Y, Nie Z, Wei P. A Chimeric Conjugate of Antibody and Programmable DNA Nanoassembly Smartly Activates T Cells for Precise Cancer Cell Targeting. Angew Chem Int Ed 2022;61. [DOI: 10.1002/anie.202205902] [Reference Citation Analysis]
7 Zhang P, Zhang Y, Ji N. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions. Front Immunol 2022;13:927132. [DOI: 10.3389/fimmu.2022.927132] [Reference Citation Analysis]
8 Finck AV, Blanchard T, Roselle CP, Golinelli G, June CH. Engineered cellular immunotherapies in cancer and beyond. Nat Med 2022;28:678-89. [PMID: 35440724 DOI: 10.1038/s41591-022-01765-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
9 Manry D, Bolanos K, DiAndreth B, Mock JY, Kamb A. Robust In Vitro Pharmacology of Tmod, a Synthetic Dual-Signal Integrator for Cancer Cell Therapy. Front Immunol 2022;13:826747. [PMID: 35359952 DOI: 10.3389/fimmu.2022.826747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ahmadi S, Sukprasert P, Vegesna R, Sinha S, Schischlik F, Artzi N, Khuller S, Schäffer AA, Ruppin E. The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective. Nat Commun 2022;13:1613. [PMID: 35338126 DOI: 10.1038/s41467-022-29154-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sandberg ML, Wang X, Martin AD, Nampe DP, Gabrelow GB, Li CZ, McElvain ME, Lee WH, Shafaattalab S, Martire S, Fisher FA, Ando Y, Liu E, Ju D, Wong LM, Xu H, Kamb A. A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo. Sci Transl Med 2022;14:eabm0306. [PMID: 35235342 DOI: 10.1126/scitranslmed.abm0306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Tokatlian T, Asuelime GE, Mock J, Diandreth B, Sharma S, Toledo Warshaviak D, Daris ME, Bolanos K, Luna BL, Naradikian MS, Deshmukh K, Hamburger AE, Kamb A. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells. J Immunother Cancer 2022;10:e003826. [DOI: 10.1136/jitc-2021-003826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Buechner J, Caruana I, Künkele A, Rives S, Vettenranta K, Bader P, Peters C, Baruchel A, Calkoen FG. Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant? Front Pediatr 2022;9:784024. [DOI: 10.3389/fped.2021.784024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Figueroa I, Gupta A, Peighambari A. T-Cell Based Therapies: Clinical Applications and Challenges. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_185-1] [Reference Citation Analysis]
15 Sloas C, Gill S, Klichinsky M. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Front Immunol 2021;12:783305. [PMID: 34899748 DOI: 10.3389/fimmu.2021.783305] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 8.5] [Reference Citation Analysis]
16 Hu Z, Yuan J, Long M, Jiang J, Zhang Y, Zhang T, Xu M, Fan Y, Tanyi JL, Montone KT, Tavana O, Chan HM, Hu X, Vonderheide RH, Zhang L. The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat Cancer 2021;2:1406-22. [PMID: 35121907 DOI: 10.1038/s43018-021-00282-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
17 Savanur MA, Weinstein-Marom H, Gross G. Implementing Logic Gates for Safer Immunotherapy of Cancer. Front Immunol 2021;12:780399. [PMID: 34804073 DOI: 10.3389/fimmu.2021.780399] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Richards RM, Zhao F, Freitas KA, Parker KR, Xu P, Fan A, Sotillo E, Daugaard M, Oo HZ, Liu J, Hong WJ, Sorensen PH, Chang HY, Satpathy AT, Majzner RG, Majeti R, Mackall CL. NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. Blood Cancer Discov 2021;2:648-65. [PMID: 34778803 DOI: 10.1158/2643-3230.BCD-20-0208] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
19 Cubillos-Ruiz A, Guo T, Sokolovska A, Miller PF, Collins JJ, Lu TK, Lora JM. Engineering living therapeutics with synthetic biology. Nat Rev Drug Discov 2021;20:941-60. [PMID: 34616030 DOI: 10.1038/s41573-021-00285-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 18.0] [Reference Citation Analysis]
20 Simon S, Bugos G, Salter AI, Riddell SR. Synthetic receptors for logic gated T cell recognition and function. Curr Opin Immunol 2021;74:9-17. [PMID: 34571290 DOI: 10.1016/j.coi.2021.09.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, Cho J, Briones JD, Duecker JM, Goretsky YE, Dannenfelser R, Cardarelli L, Troyanskaya O, Sidhu SS, Roybal KT, Okada H, Lim WA. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med 2021;13:eabe7378. [PMID: 33910979 DOI: 10.1126/scitranslmed.abe7378] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 40.0] [Reference Citation Analysis]
22 Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, Montgomery G, Liu B, Roybal KT. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med 2021;13:eabd8836. [PMID: 33910981 DOI: 10.1126/scitranslmed.abd8836] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 20.5] [Reference Citation Analysis]
23 Banerjee R, Shah N, Dicker AP. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health. JCO Clin Cancer Inform 2021;5:668-78. [PMID: 34110929 DOI: 10.1200/CCI.21.00023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Guo F, Cui J. CAR-T in Cancer Treatment: Develop in Self-Optimization, Win-Win in Cooperation. Cancers (Basel) 2021;13:1955. [PMID: 33921581 DOI: 10.3390/cancers13081955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Fiorenza S, Turtle CJ. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success. BioDrugs 2021;35:281-302. [PMID: 33826079 DOI: 10.1007/s40259-021-00477-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
26 Schoenfeld AJ, O'Cearbhaill RE. How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors? Cancer J 2021;27:134-42. [PMID: 33750073 DOI: 10.1097/PPO.0000000000000516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Williams JZ, Allen GM, Shah D, Sterin IS, Kim KH, Garcia VP, Shavey GE, Yu W, Puig-Saus C, Tsoi J, Ribas A, Roybal KT, Lim WA. Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science 2020;370:1099-104. [PMID: 33243890 DOI: 10.1126/science.abc6270] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 24.5] [Reference Citation Analysis]
28 Jacome DA, Northrup JD, Ruff AJ, Reilly SW, Lee IK, Blizard GS, Sellmyer MA. A Chemical Approach for Programmable Protein Outputs Based on Engineered Cell Interactions. ACS Chem Biol 2021;16:52-7. [PMID: 33351606 DOI: 10.1021/acschembio.0c00935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Lee S, Wong WW. The Most Logical Approach to Improve CAR T Cell Therapy. Cell Syst 2020;11:421-3. [PMID: 33212015 DOI: 10.1016/j.cels.2020.10.008] [Reference Citation Analysis]
30 Ahmadi S, Sukprasert P, Vegesna R, Sinha S, Schischlik F, Artzi N, Khuller S, Schäffer AA, Ruppin E. The Landscape of Receptor-Mediated Precision Cancer Combination Therapy: A Single-Cell Perspective.. [DOI: 10.1101/2020.01.28.923532] [Reference Citation Analysis]